Abstract:Many preclinical studies have demonstrated the stimulative effect of STING agonists in immunotherapy, but their adverse effects prevent practical use. Previous research by our team found that STING has a more significant anti-tumor role in host immune cells than tumor cells, and the level of STING mRNA is related to the outcome of immunotherapy in non-small cell lung cancer. Although STING is necessary for CD8+T cells to exert immunological activity, its effect on CD8+T cells is debatable. Therefore, we will concentrate on the particular roles of STING in CD8+T cells. We used in vitro and in vivo models to confirm the influence of STING on CD8+T cell function. We examined the impact of STING on CD8+T cell metabolic function using RNA-seq, seahorse, flow, electron microscopy, and other techniques. STING knockout mice were used to study the effect of competitive inhibition of glycolytic products during immunotherapy. RNA-seq showed significant changes in signaling pathways such as glycolysis/glycogen synthesis, oxidative phosphorylation, tricarboxylic acid cycle, and one carbon unit in STING-/- CD8+T cells. In vitro experiments revealed that the inactivation of the STING gene reduced the number of mitochondria, altered the choice of metabolic pathways, and impaired the anti-tumor ability. Flow results showed that the mean fluorescence intensity of mitochondria in STING-/- CD8+T decreased. Seahorse experiment showed that STING-/- CD8+T glycolysis was enhanced, and oxidative phosphorylation was decreased. Meanwhile, the content of lactic acid in the culture supernatant of STING-/- CD8+T increased dramatically, the high level of lactic acid further inhibited the proliferation of CD8+T and the secretion of IFN-γ. Competitive inhibition of the glycolysis process or lactic acid formation can save the function of STING-/- CD8+T cells and the secretion of IFN-γ, save the immunotherapy effect of STING-/- mice. This provides a new therapeutic idea for patients with low STING expression and poor immunotherapy response. Our study is the first to explore the effect of STING on the metabolic process in CD8+ T cells. Intervening in the metabolic process of STING-deficient CD8+ T can save the efficacy of immunotherapy.

Recombinant immunotoxin induces tumor intrinsic STING signaling against head and neck squamous cell carcinoma

Discovery of Novel Thieno[2,3-d]imidazole Derivatives As Agonists of Human STING for Antitumor Immunotherapy Using Systemic Administration.

Structure−Activity Relationship Study of Benzothiophene Oxobutanoic Acid Analogues Leading to Novel Stimulator of Interferon Gene (STING) Agonists

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

Structural Insights into a Shared Mechanism of Human STING Activation by a Potent Agonist and an Autoimmune Disease-Associated Mutation.

Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy

Synthetic Enforcement of STING Signaling in Cancer Cells Appropriates the Immune Microenvironment for Checkpoint Inhibitor Therapy.

STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity

STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade

STING-mediated DNA sensing in cancer immunotherapy

Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulation

495P Intrinsic STING of CD8+T Cells Regulates Self-Metabolic Reprogramming and Exerts Anti-Tumor Effects

Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses

Systemic Administration of STING Agonist Promotes Myeloid Cells Maturation and Antitumor Immunity Through Regulating Hematopoietic Stem and Progenitor Cell Fate

Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response

Hainanenin-1, an oncolytic peptide, triggers immunogenic cell death via STING activation in triple-negative breast cancer

Stimulator of Interferon Genes Pathway Activation through the Controlled Release of STINGel Mediates Analgesia and Anti-Cancer Effects in Oral Squamous Cell Carcinoma

STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells

Targeting STING signaling for the optimal cancer immunotherapy

Sono-Driven STING Activation Using Semiconducting Polymeric Nanoagonists for Precision Sono-Immunotherapy of Head and Neck Squamous Cell Carcinoma

Abstract LB114: STING licensing of type I dendritic cells potentiates antitumor immunity